Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MET-4

PreclinicalSmall molecule

UUniversity Health Network, Toronto

MET-4 is one of 88 small molecule programs targeting Immunotherapy. It is currently in Preclinical.

3

Indications

3

Total Trials

2

Active Trials

87

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunotherapyActive, not recruiting

ALL Solid TumorsActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

ImmunotherapyPreclinical

Active, not recruiting

ALL Solid TumorsPreclinical

Active, not recruiting

Squamous Cell CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

76 competitors in Immunotherapy

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Keytruda

Tecentriq

Taxol

Paraplatin

Yervoy

Bristol-Myers Squibb

Imfinzi

Herceptin

Abraxane

Bristol-Myers Squibb

Trexall

Jazz Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

ALL Solid Tumors

NCT03686202

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

Active, not recruiting·UUniversity Health Network, Toronto·N/A·NCT03838601·30 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Withdrawn·CCanadian Cancer Trials Group·Phase 2·NCT05743777

All Solid Tumors1 trial

Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)

Active, not recruiting·UUniversity Health Network, Toronto·Preclinical·NCT03686202·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MET-4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MET-4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MET-4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Health Network, Toronto

Related News